Dr. Reddy's Laboratories launches generic version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100mg, a therapeutic equivalent generic version of Kuvan® (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the U.S. Food and Drug Administration (USFDA).

"We are pleased to launch this generic version of Sapropterin Dihydrochloride Powder for Oral Solution, illustrating our continued commitment to bring affordable generic medicines to market for patients," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories. "At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease."

Dr. Reddy's Sapropterin Dihydrochloride Powder for Oral Solution, is available in 100 mg unit dose packets in a 30 count carton.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4617.55 as compared to the previous close of Rs. 4556.05. The total number of shares traded during the day was 23993 in over 2828 trades.

The stock hit an intraday high of Rs. 4639.2 and intraday low of 4545.75. The net turnover during the day was Rs. 110693728.

Source : Equity Bulls

Keywords